Results 151 to 160 of about 110,008 (267)

A novel treatment score (QUAD score) to promote treatment optimization in heart failure with a reduced ejection fraction

open access: yesESC Heart Failure, EarlyView.
The QUAD score was developed to promote adherence to clinical practice guidelines for patients with heart failure and a reduced left ventricular ejection fraction <50%. In newly diagnosed patients who had completed therapy titration, we found that patients with an excellent QUAD score had a significant reduction in the risk of mortality or ...
Henry Oluwasefunmi Savage   +23 more
wiley   +1 more source

Congestion, decongestion, renal function and diuretics in (ESC) heart failure

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 730-732, April 2025.
Jan Biegus   +2 more
wiley   +1 more source

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

open access: yesESC Heart Failure, EarlyView.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra   +25 more
wiley   +1 more source

A case of pulmonary hyperinflation in chronic heart failure: role of diuretic therapy and cardiorespiratory rehabilitation

open access: gold, 2011
Claudio Di Gioia   +8 more
openalex   +2 more sources

Early Versus Delayed Diuretic Administration and Urine-Guided Strategies in Acute Decompensated Heart Failure: A Systematic Review of Clinical Outcomes. [PDF]

open access: yesCureus
Muzammil R   +11 more
europepmc   +1 more source

Nephrological perspectives on the underutilization of SGLT2is in heart failure and chronic kidney disease

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1490-1491, April 2025.
Özant Helvacı   +4 more
wiley   +1 more source

Re‐PERFUSE: Phase 1b study of AZD3427, a novel relaxin receptor agonist, on renal perfusion in HFrEF patients

open access: yesESC Heart Failure, EarlyView.
Abstract Aims Renal impairment frequently coexists with heart failure (HF) and is associated with increased risk of poor clinical outcomes. This highlights the urgent need for therapies targeting both cardiac and renal dysfunction. AZD3427, a long‐acting recombinant fusion protein and relaxin analogue that selectively activates the relaxin family ...
Marcin Ufnal   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy